Neuro-first · SF · NY
Operator-led neurotech investing.
The brain will define the next century of medicine. Frontier AI is making the invisible visible. We back the systems designed to transform human health.
Founding philosophy
The neurotech wave is here.
CNS / Neuro M&A · 2025
$30.7B
Surpassed oncology for the first time in the modern biopharma era.
Acquisition premium
39%
Average premium strategics paid for neuro & CNS targets — they're paying up for the brain.
Neuro device market
12% CAGR
$20.2B → $35.7B by 2030 — the fastest-growing segment in medtech.
Patient population
3B+
People living with neurological disorders — the largest untapped population in medicine.
Pharma already called it. Facing a roughly $300B patent cliff, the largest acquirers are buying their way into the brain — CNS dealmaking overtook oncology for the first time ever, at premium valuations. The base technology has caught up: AI signal decoding and closed-loop stimulation have turned neuro devices into adaptive therapeutic systems. Validated biology, mature tools, motivated acquirers — the conditions for a neurotech boom are in place.
Three domains. One intersection.
Physical systems.
Proprietary devices and hardware platforms with defensible intellectual property and scalable design.
Biological signals.
High-fidelity physiological data streams that generate durable, proprietary assets.
Applied intelligence.
Computational systems that transform biological signals into actionable insights.
Companies we've backed.
Neurotech innovation operates within defined structural constraints. Through deep diligence we predict and mitigate these risks, prioritizing investment in companies designed for those realities from inception with clear differentiation and venture-scale return potential.
Operators, not spectators.
We've built the companies we now back. Our partners and advisors have operated at the center of modern neurotech — Nexus NeuroTech Ventures, Verily, Boston Scientific, Apple, Deerfield Catalyst, Coridea, Lightstone Ventures, MedMountain Ventures, and Lurie Children's — taking devices from prototype through FDA clearance and acquisition. Ground Effect runs an operator-led, partner-only model: a tight team of equal partners with no associates or junior staff, so founders work directly with senior operators. We bring technical depth, clinical judgment, and hands-on support — product and regulatory strategy, clinical validation, and commercial scaling — sharpened by a world-class advisory bench and a network built at Nexus NeuroTech Ventures, anchored in the BrainTech Alliance we co-founded.
